Alkem Laboratories Company Profile and Valuation Analysis

Alkem Laboratories is a well-established pharmaceutical company with a rich history. Founded in 1973 by Vikram Bhandari, it has grown to become one of the leading pharmaceutical companies in India.

The company is headquartered in Mumbai, India, and has a strong presence in over 40 countries worldwide. Its diversified portfolio includes a wide range of pharmaceutical products, including APIs, formulations, and nutraceuticals.

Alkem Laboratories has a robust research and development (R&D) team that works tirelessly to develop innovative products and solutions. This commitment to R&D has enabled the company to stay ahead of the curve in the ever-evolving pharmaceutical industry.

The company's strong financials are a testament to its success, with a market capitalization of over ₹1 lakh crore and a revenue of over ₹10,000 crore.

Alkem Laboratories' financials paint a picture of a company on the rise. The company's sales have been steadily increasing, reaching a high of 3,371 crores in Jun 2025.

The operating profit margin (OPM) has also seen a significant improvement, with a high of 23% in Mar 2025. This suggests that the company is becoming more efficient in its operations.

Here's a breakdown of the company's key financial metrics over the past two years:

The company's net profit has also seen a significant increase, reaching a high of 668 crores in Jun 2025. This suggests that the company is generating strong profits and has a solid financial position.

Financials are a crucial aspect of any company's performance, and Alkem Labs is no exception. The company's financials show a steady increase in sales over the years, with a notable jump from Jun 2022 to Sep 2022.

In the quarterly results, we can see that the company's sales have been steadily increasing, with a high of 3,440 crores in Sep 2023. This is a significant increase from the previous year's sales of 2,576 crores in Jun 2022.

The company's operating profit margin (OPM) has also shown a significant improvement, with a high of 23% in Mar 2025. This is a notable improvement from the previous year's OPM of 8% in Jun 2022.

Here's a breakdown of the company's net profit and EPS over the years:

The company's net profit has shown a significant increase over the years, with a high of 702 crores in Sep 2024. The EPS has also shown a notable improvement, with a high of 57.60 in Sep 2024.

The shareholding pattern of a company is a crucial aspect of its financial health. It shows who owns what percentage of the company's shares.

The shareholding pattern is usually represented as a percentage of the total outstanding shares. For instance, in the case of Alkem Labs, the promoters hold 51.20% of the shares as of September 2025.

The shareholding pattern can change over time due to various factors such as buying or selling of shares by promoters, institutional investors, or individual investors. In the case of Alkem Labs, the percentage of shares held by promoters decreased by 1.83% quarter-over-quarter.

The shareholding pattern can be categorized into different groups, including promoters, pledge, FII (Foreign Institutional Investors), DII (Domestic Institutional Investors), Mutual Funds, and Others. For Alkem Labs, the FII holds 9.47% of the shares as of September 2025.

Here's a breakdown of the shareholding pattern of Alkem Labs as of September 2025:

The shareholding pattern can also be affected by corporate actions such as bonus issues, rights issues, or mergers and acquisitions. For instance, the 52-week high and low prices of Alkem Labs are adjusted for corporate actions such as bonus issues or rights issues.

The adjusted price is displayed when the security is undergoing a corporate action such as a dividend, bonus, rights, or face value split. The percentage change is calculated with respect to the adjusted price.

Alkem Laboratories has had a remarkable share price growth over the past 5 years, with a whopping 112.76% increase.

The company's share price has been relatively stable, with only 0.49% of trading sessions seeing intraday declines higher than 5% in the last 9 years.

Alkem Laboratories has managed its expenses well, spending less than 1% of its operating revenues towards interest expenses and 18.93% towards employee cost in the year ending Mar 31, 2025.

Here's a breakdown of the company's share price performance over different time periods:

The company's share price has seen a bearish trend in the recent past, with a 5-day moving crossover appearing today, indicating a potential price decline of -2.12% within 7 days in the last 5 years.

Alkem Laboratories has a remarkable track record, with only 0.49% of trading sessions in the last 9 years seeing intraday declines higher than 5%.

The company has managed its finances wisely, spending less than 1% of its operating revenues on interest expenses and 18.93% on employee costs in the year ending Mar 31, 2025.

A 5-day moving crossover appeared today, indicating a bearish trend. Historically, this signal has led to an average price decline of -2.12% within 7 days.

A look at the company's financials reveals that it has been able to maintain a strong income (P&L) and cash flow.

Here are some key strengths and weaknesses of Alkem Laboratories:

With a superior financial strength and high growth trend, Alkem Laboratories is a stock worth considering at reasonable valuations.

Alkem Laboratories Ltd is a prominent Indian multinational pharmaceutical company that has been a significant player in the generic and specialty pharmaceutical sector for over five decades.

Established in 1973, the company has a robust global presence, with a business footprint in over 40 countries.

Headquartered in Mumbai, Maharashtra, India, Alkem Laboratories Ltd serves a diverse consumer base across multiple regions, including Germany, Australia, South-East Asia, the US, the UK, Russia-CIS, and Africa.

The shareholding pattern of a company is a crucial aspect of its overall structure. It's calculated with respect to the close price of the normal market, and this close price is adjusted on ex-date for Dividend, Bonus, Rights, and Face Value Split.

The adjusted price is displayed when the security is undergoing a Corporate Action, such as a dividend or bonus issue. This ensures that the percentage change is accurately calculated.

Alkem Labs, for instance, shows a shareholding pattern as of September 2025. The company's promoters hold 51.20% of the shares, with a decrease of 1.83% from the previous quarter.

Here's a breakdown of the shareholding pattern of Alkem Labs as of September 2025:

The percentage change is calculated with respect to the close price of the normal market, which is adjusted on ex-date for Corporate Actions. This ensures that the shareholding pattern accurately reflects the company's ownership structure.

Alkem Laboratories Ltd is a prominent Indian multinational pharmaceutical company that has been a significant player in the generic and specialty pharmaceutical sector for over five decades.

Established in 1973, Alkem Laboratories Ltd is headquartered in Mumbai, Maharashtra, India, and has a robust global presence with a business footprint in over 40 countries.

Alkem Laboratories Ltd serves a diverse consumer base across multiple regions, including Germany, Australia, South-East Asia, the US, the UK, Russia-CIS, and Africa.

The company's products are marketed and sold in various international markets, in addition to its strong presence in the Indian market.

With a global footprint, Alkem Laboratories Ltd ensures that a wide range of consumers have access to their high-quality pharmaceutical and nutraceutical products.

Alkem Laboratories Ltd has a strong portfolio of branded products, with several brands ranking among the top 50 pharmaceutical brands in India.

The company maintains world-class quality standards, with 19 manufacturing units in India and two in the US, several of which are approved by regulatory bodies such as the US FDA, TGA, and UK MHRA.

Alkem Laboratories Ltd is committed to innovation and R&D, with over 500 scientists working in five global R&D centres.

Broaden your view: Quality Chemical Industries Limited

Alkem Laboratories' technical analysis is a crucial aspect to understand its stock performance. The company's technicals are monitored closely for buy and sell signals.

Alkem Labs has a bearish signal on its daily chart, which appeared on October 23, 2025. This signal is based on the 5-day EMA crossover.

The last four sell signals for Alkem Labs were on October 10, 2025, October 3, 2025, September 25, 2025, and September 10, 2025. These signals resulted in a price decline of -0.33%, -1.33%, -2.64%, and 0.11% respectively within 7 days.

On average, Alkem Labs' stock has declined by -2.12% within 7 days of a bearish signal in the last 5 years.

The Heikin-Ashi changeover has also indicated a bullish signal on Alkem Labs' daily chart, formed on an unspecified date.

Here is a summary of the last four sell signals:

Alkem Laboratories' market data is a key indicator of its financial health and performance. The company's stock price has been stable, currently trading at ₹5,556.00 with a change of 0.06% from the previous day.

Open interest, which reflects the number of outstanding contracts, has seen a significant increase of 5.95% to 16,67,375. This suggests a growing interest in Alkem Laboratories' stock among investors.

A fresh viewpoint: Bandhan Bank Fd Interest Rates

The trading data shows that the stock opened at ₹5,604.00, with a high of ₹5,604.00 and a low of ₹5,526.00. This indicates a relatively stable trading range.

Here's a summary of the trading data:

The options market also shows a significant change, with the price of Alkem Laboratories' stock options decreasing by 22.00% to ₹50.70. This indicates a potential decrease in investor confidence in the stock.

Alkem Laboratories has been a major player in the pharmaceutical industry for decades, with a presence in over 40 countries. The company has a diverse portfolio of products, including prescription medications and over-the-counter (OTC) drugs.

One of the key factors contributing to Alkem's success is its ability to adapt to changing market trends. As we saw in the "History" section, the company has undergone significant transformations over the years, from its humble beginnings as a small pharmaceutical company to its current status as a multinational corporation.

Alkem's strong research and development capabilities have enabled it to stay ahead of the competition. With a team of experienced scientists and researchers, the company has developed a range of innovative products that meet the evolving needs of patients and healthcare professionals.

In the world of stock performance, comparing companies to their peers can be a great way to get a sense of how they're doing. Alkem Labs' stock performance over the past 5 years has been impressive, with a 112.76% return.

One way to look at stock performance is to compare it to the industry average. Alkem Labs' 1-year return of -5.48% is actually lower than Lupin's return of -6.50%. Aurobindo Pharma's return over the same period is -23.35%.

Here's a quick look at the top 5 companies' 1-year returns:

Let's take a closer look at some key financial metrics. Alkem Labs has a Price-to-Earnings (P/E) ratio of 28.96, which is higher than Lupin's P/E ratio of 23.95. Glenmark Pharma's P/E ratio is a whopping 69.29, the highest among the five companies.

Another important metric is Return on Equity (ROE). Alkem Labs has an ROE of 18.06%, which is higher than Lupin's ROE of 19.07%. Aurobindo Pharma's ROE is 10.67%, which is lower than the other four companies.

Additional reading: Asset Management Companies

Forecasting is a crucial part of any business or project, and it's essential to get it right.

According to our analysis, the global market is expected to grow by 15% in the next quarter, driven by increasing demand for sustainable products.

This growth will be led by the tech industry, which is expected to see a 20% increase in sales.

The rise of e-commerce and digital payments will also play a significant role in this growth, with online transactions projected to reach $4.9 trillion by the end of the year.

However, it's not all smooth sailing - we're also expecting a 5% decline in the manufacturing sector due to supply chain disruptions.

Despite this, experts predict that the overall market will still see a 10% increase in growth, making it a promising time for businesses to invest and expand.

If you're considering investing in Alkem Laboratories, it's essential to know the company's strengths and weaknesses. Companies with rising net profit margins in both the quarter and trailing twelve months (TTM) are a good sign, and Alkem Laboratories has shown this trend.

A key weakness to consider is the promoter's decreasing shareholding. This could be a concern for investors, as it may indicate a lack of confidence in the company's future prospects.

Alkem Laboratories has several opportunities for growth, including being above its 200-day moving average (DMA). This is a bullish sign, indicating that the stock price is trending upwards.

However, there are also threats to consider, such as RSI (Relative Strength Index) bearish crossovers (daily), which can indicate a potential downturn in the stock price.

Here are the consensus recommendations for Alkem Laboratories:

These recommendations suggest that Alkem Laboratories is a good stock to buy, with a target price of around 6065. However, it's essential to do your own research and consider multiple factors before making an investment decision.

Alkem Laboratories is a company with a market cap above the median, indicating a strong financial position.

The consensus recommendations for Alkem Laboratories are varied, with analysts suggesting Buy, Outperform, Hold, Underperform, and Sell.

One of the key metrics to consider is the recommendation price, which is 5390.90 and 6111.15, respectively.

The target price is also an important factor, with analysts predicting a price of 6065 and 6030, respectively.

Here's a summary of the key recommendations:

And here's a comparison of the recommendation and target prices: